At MedCity News we have built a name for ourselves as a must-read online publication that highlights innovation across the healthcare landscape. At no time in our 11-year history is that more important than now, as life science, health tech, medtech and healthcare organizations race against time to develop treatments for Covid-19, produce much needed
Sid Roberts, MD Lufkin Radiation OncologistMember, Texas Medical Association We are early in this coronavirus game of social distancing and hand washing. We haven’t quite become weary of it. We joke about it. And yet, I am starting to see – among my friends – some very real concern about our elder parents and grandparents.
Johns Hopkins faculty members record Instagram videos for their students with messages of support, sympathy, and encouragement as the Spring 2020 semester moves to remote learning.
Mercy Hylton, MD Indiana Pediatric Emergency Medicine Physician Editor’s note: This article originally appeared on KevinMD.com. Some advice as an emergency physician, daughter, mother, and concerned citizen. Help keep older relatives and neighbors self-quarantined at home. Same goes for those of any age who are immune-compromised (cancer-patients, on immune-suppressant meds for autoimmune diseases, etc.) Pick
Although momentum for virtual care through telemedicine and telehealth has been building for years, availability and access are on the rise as regulatory hurdles at the federal and regional level are addressed. The public health crisis presented by Covid-19 has vaulted virtual care to the forefront of the national dialogue. CMS has waived requirements that
As the novel coronavirus disease (COVID-19) continues to spread across many countries including the U.S., the outbreak is happening around the same time as another viral illness we all try to avoid this time of year: influenza. The two viruses share some clear similarities: Both are spread by contact – If you don’t want to
Employee benefits platform Accolade plans to go public, according to paperwork the company filed on Friday. The company, which has headquarters in Seattle and Plymouth Meeting, is looking to be listed on Nasdaq as ACCD, though it has not disclosed the pricing or the number of shares for its planned IPO. Accolade is focused on